Study explores racial differences in gastric cancer immunotherapy outcomes
Gastric Cancer Immunotherapy: Why Treatment Response Varies Globally Advanced gastric cancer remains a formidable challenge, with a 5-year survival rate stubbornly below 10%. Recent advances combining chemotherapy with PD-1 or PD-L1 inhibitors have become the standard first-line treatment for HER2-negative disease. However, a consistent pattern emerges from clinical trials: Asian patients often demonstrate more significant … Read more